Work

Research progress of antibody–drug conjugates in gynecologic cancer

Year: 2024

Type: article

Abstract: Gynecologic cancer is a critical concern in the field of women’s health, and traditional treatment methods have demonstrated limited efficacy for certain advanced and recurrent gynecologic cancers. In recent years, antibody–drug conjugate (ADC) therapy, as an emerging targeted approach, has gained increasing attention as a research hotspot. This review aims to elucidate the structure and mechanism of ADC drugs and explore their application and clinical research progress in gynecologic cancers such as ovarian cancer, cervical cancer, and endometrial cancer.

Source: Holistic Integrative Oncology

DOI: 10.1007/s44178-024-00114-8

Authors: Dongdong Xu, Zhe-Sheng Chen, Xuanwei Peng, Zhongqiu Lin, Huaiwu Lu

Institutions: Sun Yat-sen University, Sun Yat-sen Memorial Hospital, St. John's University

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Beijing Xisike Clinical Oncology Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province